In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, PDS Biotechnology Corporation (NASDAQ: PDSB) closed at $0.96 up 0.16% from its previous closing price of $0.96. In other words, the price has increased by $0.16 from its previous closing price. On the day, 0.53 million shares were traded. PDSB stock price reached its highest trading level at $1.0 during the session, while it also had its lowest trading level at $0.9404.
Ratios:
For a deeper understanding of PDS Biotechnology Corporation’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.92 and its Current Ratio is at 2.92. In the meantime, Its Debt-to-Equity ratio is 1.16 whereas as Long-Term Debt/Eq ratio is at 0.81.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, B. Riley Securities on November 01, 2022, initiated with a Buy rating and assigned the stock a target price of $10.
On June 28, 2021, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $25.
H.C. Wainwright Upgraded its Neutral to Buy on November 10, 2020, while the target price for the stock was maintained at $6.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 28 ’25 when Freitag Gregory Gene bought 15,060 shares for $1.66 per share. The transaction valued at 25,000 led to the insider holds 61,213 shares of the business.
Glover Stephen C. bought 15,061 shares of PDSB for $25,001 on Feb 28 ’25. The Director now owns 78,851 shares after completing the transaction at $1.66 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PDSB now has a Market Capitalization of 45341992 and an Enterprise Value of 31627158.
Stock Price History:
The Beta on a monthly basis for PDSB is 1.06, which has changed by -0.7164706 over the last 52 weeks, in comparison to a change of 0.15927899 over the same period for the S&P500. Over the past 52 weeks, PDSB has reached a high of $3.79, while it has fallen to a 52-week low of $0.85. The 50-Day Moving Average of the stock is -15.37%, while the 200-Day Moving Average is calculated to be -27.25%.
Shares Statistics:
For the past three months, PDSB has traded an average of 502.83K shares per day and 453710 over the past ten days. A total of 46.63M shares are outstanding, with a floating share count of 45.25M. Insiders hold about 3.78% of the company’s shares, while institutions hold 15.85% stake in the company. Shares short for PDSB as of 1757894400 were 1752765 with a Short Ratio of 3.49, compared to 1755216000 on 1915584. Therefore, it implies a Short% of Shares Outstanding of 1752765 and a Short% of Float of 3.8399997999999997.
Earnings Estimates
The stock of PDS Biotechnology Corporation (PDSB) is currently drawing attention from 3.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.15 and low estimates of -$0.29.
Analysts are recommending an EPS of between -$0.74 and -$0.96 for the fiscal current year, implying an average EPS of -$0.82. EPS for the following year is -$0.73, with 3.0 analysts recommending between -$0.58 and -$0.9.
